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Summary
 
Activation-induced cell death (AICD) is a process that regulates the size and the duration of the
primary immune T cell response. In this report, we investigated the mechanisms involved in
the regulation of AICD by transforming growth factor 
 
b
 
1 (TGF-
 
b
 
1). We found that TGF-
 
b
 
1
decreased apoptosis of human T cells or T cell hybridomas after activation by anti-CD3. This
decrease was associated with inhibition of Fas (Apo-1/CD95) ligand (FasL) expression, whereas
Fas signaling was not affected by TGF-
 
b
 
1. In parallel, TGF-
 
b
 
1 inhibited c-Myc expression in
T cell hybridomas, and ectopic expression of a chimeric molecule composed of c-Myc and the
steroid binding domain of the estrogen receptor (Myc-ER) blocked both the inhibition of FasL
and the decrease of AICD induced by TGF-
 
b
 
1, providing that 4-hydroxytamoxifen was
present. These results identify one mechanism by which TGF-
 
b
 
1 blocks AICD to allow the
clonal expansion of effector T cells and the generation of memory T cells during immune re-
sponses.
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T
 
ransforming growth factor (TGF)-
 
b
 
1 is a multifunc-
tional cytokine that regulates cell growth, adhesion,
and differentiation in a wide variety of cell types (1). In the
immune system, TGF-
 
b
 
1 controls the growth and differ-
entiation of T cells, B cells, NK cells, and dendritic cells
(2–7). TGF-
 
b
 
1 has also been shown to be effective in
treating experimental allergic encephalomyelitis and col-
lagen-induced arthritis, two T cell–mediated experimental
autoimmune diseases (8–10). In contrast, the expansion of
T lymphocytes expressing a naive surface phenotype can be
enhanced rather than suppressed by TGF-
 
b
 
1 (7, 11, 12).
TGF-
 
b
 
1 may be one of the candidate molecules in-
volved in memory and effector T cell generation. Indeed,
TGF-
 
b
 
1 has recently been implicated in the generation of
a large population of effector CD4
 
1
 
 T cells in response to
antigen stimulation (13, 14). Furthermore, in this system
TGF-
 
b
 
1 did not affect proliferation or influence cytokine
secretion but partially blocked activation-induced apoptosis
(13, 14). The protective effect of TGF-
 
b
 
1 on activation-
induced cell death (AICD)
 
1
 
 has also been reported for
CD8
 
1
 
 T cells (12).
AICD in T cells in vivo has been proposed to limit the
expansion of an immune response by eliminating effector
cells that are no longer needed (15). Indeed, after antigen
or pathogens have been eliminated from the organism,
these T cells are potentially dangerous because of their po-
tent effector functions and low activation requirements.
We and others recently reported that activation of T cell
clones, T cell lines, or T cell hybridomas induces FasL ex-
pression and that interaction between Fas and its ligand is
the major mechanism involved in AICD (16–20).
The expression of FasL during AICD requires the activa-
tion of transcription factors. Previous studies using 
 
c-myc
 
antisense oligonucleotides (21) or dominant negative recip-
rocal exchange mutants of Myc or Max (22), which antag-
onize the functional Myc/Max heterodimer, demonstrated
that c-Myc function is required for AICD in T cells. More
recently, Hueber et al. (23) reported that 
 
c-myc
 
–induced
apoptosis of serum-starved fibroblasts requires the expres-
sion of Fas and FasL. Therefore, it appears that c-Myc may
be essential for the function of FasL and subsequent apop-
tosis in some systems.
TGF-
 
b
 
1 has been reported to exert its growth inhibitory
effects on various cell types through the downregulation of
the expression of genes involved in cellular proliferation,
such as cyclin-dependent kinases (CDKs [24–26]), and the
 
c-myc
 
 protooncogene (27, 28). Furthermore TGF-
 
b
 
1 sup-
 
1
 
Abbreviations used in this paper:
 
 AICD, activation-induced cell death; AS,
antisense; CDK, cyclin-dependent kinase; CsA, cyclosporine A; NF, nu-
clear factor; NS, nonsense; 4-OHT, 4-hydroxytamoxifen; RT, reverse
transcription. 
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presses constitutive and inducible c-Myc expression in two
constitutively activated murine T clones (29).
In this report, we investigated the mechanisms involved
in the regulation of AICD by TGF-
 
b
 
1. We determined
that TGF-
 
b
 
1 inhibits FasL expression at the level of
mRNA expression. TGF-
 
b
 
1 also inhibits the constitutive
c-Myc expression in A1.1 T cell hybridomas, and since
c-Myc has been demonstrated to regulate AICD, we pre-
pared stable transfectants constitutively expressing a chi-
meric molecule composed of c-Myc and the steroid bind-
ing domain of the estrogen receptor (Myc-ER). In these
cells, TGF-
 
b
 
1 did not inhibit FasL expression and subse-
quent AICD after anti-CD3 antibody treatment, providing
that 4-hydroxytamoxifen (4-OHT) was present. These re-
sults demonstrate that TGF-
 
b
 
1 inhibits FasL expression and
subsequent AICD via downregulation of c-Myc expres-
sion.
 
Materials and Methods
 
Cell Cultures and Reagents.
 
The T cell hybridomas A1.1 and
2B4.11 have been described previously (17, 30). PBMCs were
isolated from healthy donors by density gradient centrifugation of
heparinized blood on a layer of histopaque (Sigma). All cells were
grown in RPMI 1640 medium containing 10% FCS, 5 
 
3 
 
10
 
2
 
5
 
 M
 
b
 
-mercaptoethanol, 2 mM 
 
l
 
-glutamine, and 100 U/ml each of
penicillin and streptomycin (complete medium). PMA, iono-
mycin, cyclosporine A (CsA), 4-OHT, and M2 anti-Flag anti-
body were purchased from Sigma. The mouse anti–human CD3
(OKT3) and the hamster anti–mouse CD3
 
e
 
 (145-2C11) antibod-
ies were purified from the culture supernatant by protein A affin-
ity chromatography. Phosphorothioate antisense 
 
c-myc
 
 (AS
 
c-myc
 
)
5
 
9
 
-CACGTTGAGGGGCAT-3
 
9
 
 and nonsense 
 
c-myc
 
 (NS
 
c-myc
 
)
5
 
9
 
-AGTGGCGGAGACTCT-3
 
9
 
 oligonucleotides were purchased
from Quality Controlled Biochemicals, Inc. Soluble recombinant
human FasL was obtained from Dr. Jurg Tschopp (University of
Lausanne, Epalinges, Switzerland [31]).
 
Induction and Analysis of Apoptosis.
 
For the induction of apop-
tosis, T cell hybridomas (0.5 
 
3 
 
10
 
6
 
/ml) were cultured 16 h in
triplicate in 96-well plates precoated with anti-CD3 antibody
(2C11). PBMCs (10
 
6
 
/ml) were activated for 6 d with 100 ng/ml
OKT3, and after elimination of dead cells, were restimulated
with PMA (50 ng/ml) and ionomycin (1 
 
m
 
g/ml) for 16 h. Viabil-
ity was assessed by addition of 5 
 
m
 
g/ml propidium iodide and im-
mediate analysis using a FACScan
 
®
 
 (Becton Dickinson). Dead
cells were identified as those taking up the dye. Apoptosis was
confirmed by morphological inspection by fluorescent micro-
scope after staining with 10 
 
m
 
g/ml Hoechst 33342 (Sigma).
Activation-induced FasL expression on the A1.1 murine T cell
hybridoma was assessed by determining the ability of these cells
to cause DNA fragmentation in Fas
 
1
 
 target cells as described pre-
viously (17). In brief, A1.1 cells were activated with plate-bound
anti-CD3 antibodies in the presence or absence of different con-
centrations of TGF-
 
b
 
1 and cultured for 6 h to allow FasL expres-
sion. The cells were washed twice and incubated for another 8 h
with [
 
3
 
H]TdR-labeled L1210 or L1210-Fas target cells. In other
experiments, TGF-
 
b
 
1 was added at 6 h to determine its effect on
the induction of Fas-mediated death in the target cells. [
 
3
 
H]TdR-
labeled unfragmented DNA was harvested on glass fiber filters
and assessed in a liquid scintillation counter. DNA fragmentation
was calculated as follows: % DNA fragmentation
 
 5 
 
100 
 
3 
 
(cpm
 
control group 
 
2 
 
cpm experimental group/cpm control group) 
 
6
 
SD. No DNA fragmentation was observed when target cells were
cultured with anti-CD3 in the absence of T cell hybridomas or
with T cell hybridomas in the absence of anti-CD3.
 
DNA Gel Electrophoresis.
 
DNA preparations were obtained
following a procedure described previously (32). In brief, 2 
 
3 
 
10
 
6
 
2B4.11 cells were lysed in buffer containing 10 mM EDTA, 100
mM NaCl, 0.5% (wt/vol) SDS, 100 mM Tris-HCl, pH 7.4, and
0.1 mg/ml proteinase K (Boehringer Mannheim). The DNA was
extracted twice with phenol and twice with chloroform/isoamyl
alcohol. The aqueous phase was precipitated with 2 vol of etha-
nol. The pellet was discarded, and one tenth of the volume of 3 M
sodium acetate was added to the supernatant which was left at
 
2
 
20
 
8
 
C overnight. The precipitate was centrifuged and the pellet
was dried under vacuum before resuspension in 100 
 
m
 
l RNase
buffer containing 10 mM Tris and 1 mM EDTA, pH 7.5. The
samples were diluted in loading buffer and loaded onto a 2% aga-
rose gel containing 0.1 
 
m
 
g/ml ethidium bromide (Sigma). After
electrophoresis, gels were examined under UV light.
 
RT-PCR for fas, fasL, and c-myc Expression.
 
The expression of
 
fas
 
, 
 
fasL
 
, and 
 
c-myc
 
 was determined by reverse transcription (RT)
of total RNA followed by PCR amplification (RT-PCR). Ap-
proximately 3 
 
3 
 
10
 
6
 
 cells were homogenized with 1 ml Trizol
reagent (GIBCO BRL), and total RNA was isolated according to
the manufacturer’s protocol. cDNAs were synthesized by exten-
sion of (dT) primers with 200 U of SuperScript II reverse tran-
scriptase (GIBCO BRL) in a mixture containing 1 
 
m
 
g of total
RNA digested by RNase-free DNase (2 U/
 
m
 
g of RNA) for 15 min
at 37
 
8
 
C. PCR of the cDNA was performed in a final volume of 50
 
m
 
l containing all four dNTPs, 2 mM MgCl
 
2
 
, 2.5 U of AmpliTaq
(GIBCO BRL), and each primer at 0.2 
 
m
 
M using the geneAmp
2400 PCR system (Perkin Elmer Corp.). The amplification cycles
were 94
 
8
 
C for 1 min, 55
 
8
 
C for 1 min, and 72
 
8
 
C for 1 min. The
PCR products were separated by electrophoresis on a 1.5% agarose
gel after 27–33 cycles for mouse 
 
fas
 
, 
 
fasL
 
, and 
 
c-myc
 
 or 22–28 cy-
cles for mouse 
 
b
 
-actin and visualized by ethidium bromide staining.
Amplification of 
 
b
 
-actin served as a control for sample loading and
integrity. The following primers were designed to discriminate be-
tween the amplification of cDNA (low size PCR products) and con-
taminating genomic cDNA (high size PCR products): mouse 
 
fasL
 
sense, 5
 
9
 
-CAG-CAG-TGC-CAC-TTC-ATC-TTG-G-3
 
9
 
; mouse
 
fasL
 
 antisense, 5
 
9
 
-TTC-ACT-CCA-GAG-ATC-AGA-GCG-G-3
 
9
 
;
mouse 
 
fas
 
 sense, 5
 
9
 
-GAG-GAC-TGC-AAA-ATG-AAT-GGG-G-
3
 
9
 
; mouse 
 
fas
 
 antisense, 5
 
9
 
-ACA-ACC-ATA-GGC-GAT-TTC-
TGG-G-3
 
9
 
; mouse c-myc sense, 5
 
9
 
-ACA-GAG-GGA-GTG-
AGC-GGA-CG-3
 
9
 
; mouse c-myc antisense, 5
 
9
 
-TTC-ACG-TTG-
AGG-GGC-ATC-G-3
 
9
 
; mouse 
 
b
 
-actin sense, 5
 
9
 
-TGG-AAT-
CCT-GTG-GCA-TCC-ATG-AAA-C-3
 
9
 
; and mouse 
 
b
 
-actin an-
tisense: 5
 
9
 
-TAA-AAC-GCA-GCT-CAG-TAA-CAG-TCC-G-3
 
9
 
.
 
Plasmids and Transfections.
 
Moloney retroviral virions were
produced as described previously (33). In brief, amphotropic
packaging cell line was plated at 2.5 3 106 cells/10-cm2 culture
dish for 18–24 h before transfection as described (34). Cells were
transfected with 7.5 mg of pBABE puroMyc-ER G525R con-
struct (35) using a standard calcium phosphate protocol except for
chloroquine (25 mM final), which was added to the cells 5 min
before addition of calcium phosphate DNA precipitate. After 24 h
the cells were gently washed, and fresh medium was added. Vi-
rus-containing supernatant was harvested at 24 and 48 h after
transfection, filtered, and stored at 48C. For virus infection, A1.1
cells (0.5 3 106/ml) were resuspended in 3 ml of viral superna-
tant containing 5 mg/ml polybrene for 12 h. Cells were then
washed and resuspended in RPMI medium without phenol red233 Genestier et al.
Figure 1. TGF-b1 decreases
AICD in human peripheral
blood T cells and murine T cell
hybridomas. (A) PBMCs were
activated for 6 d with OKT3
(100 ng/ml) and then restimu-
lated with PMA (50 ng/ml) and
ionomycin (1 mg/ml) (P1I) for
16 h with the indicated concen-
tration of TGF-b1 or CsA (100
ng/ml). Viability was assessed by
propidium iodide uptake and an-
alyzed using a FACScan®. Apop-
tosis was confirmed by morpho-
logical assessment after staining
with Hoechst 33342 at 10 mg/ml
(not shown). (B) A1.1 or 2B4.11
T hybridoma cells were left un-
activated (open symbols) or were activated (filled symbols) for 16 h with anti-CD3 antibody (2C11) in the presence of the indicated concentration of
TGF-b1. Viability was assessed as in A. (C) A1.1 T hybridoma cells were cultured with medium alone or activated for 12 h with anti-CD3 antibody in
the presence of the indicated concentrations of TGF-b1 (ng/ml) or CsA (100 ng/ml). DNA fragmentation associated with apoptosis was assessed by aga-
rose gel electrophoresis.
(GIBCO BRL) containing 10% steroid-free FCS, 5 3 1025 M
b-mercaptoethanol, 2 mM l-glutamine, and 100 U/ml each of
penicillin and streptomycin. 48 h after transfection, cells were se-
lected with puromycin (1.5 mg/ml) for 7 d.
Assessment of c-Myc and Myc-ER Proteins. 2 3 106 A1.1 or A1.1
Myc-ER cells were incubated with or without 10 ng/ml TGF-b1
for 8 h. Cells were then harvested, washed once in PBS, and
lysed in 100 ml 13 SDS-PAGE sample buffer (50 mM Tris, pH
6.8, 100 mM dithiothreitol, 2% SDS, 10% glycerol). Equal vol-
umes of samples (30 ml) were separated on an 8% gel and trans-
ferred to a nitrocellulose membrane (Amersham Pharmacia Bio-
tech). Membranes were blocked with 5% nonfat dry milk in
TBS, 0.02% sodium azide for 2 h and then incubated with mouse
anti–human c-Myc 9E10 (1:1,000; Santa Cruz Biotechnology,
Inc.) for 4 h at room temperature. Membranes were then washed
three times in TBS, 0.1% Tween 20 for 15 min and incubated with
a rabbit anti–mouse horseradish peroxidase conjugate (1:2,000;
Amersham Pharmacia Biotech) for 1 h. After three washes, mem-
branes were incubated with ECL chemiluminescence detection
solutions (Amersham Pharmacia Biotech) and exposed to x-ray
films for 1 min.
Cell Cycle Analysis. Cell cycle analysis was performed as de-
scribed previously (36), with slight modifications. 106 A1.1 cells
were washed twice in PBS and resuspended in 0.5 ml of hypo-
tonic fluorochrome solution (50 mg/ml propidium iodide and
0.1% Triton X-100 in 0.1% sodium citrate). After 4 h at 48C in
the dark, the fluorescence of gated live cells was analyzed using a
FACScan® flow cytometer (Becton Dickinson).
Results
TGF-b1 Decreases AICD in Human T Cells as well as
Mouse T Cell Hybridomas. TGF-b1 has been reported to
increase long-term cell expansion of Th2 cells by decreas-
ing activation-induced apoptosis in human T cells (14). To
confirm these data, we activated PBMCs for 6 d with anti-
CD3, before restimulation with PMA plus ionomycin for
16 h in the presence or absence of increasing concentra-
tions of TGF-b1. CsA, which has been shown to effec-
tively inhibit AICD (37), was used as a positive control. As
illustrated in Fig. 1 A, activated PBMCs restimulated by
addition of PMA plus ionomycin showed z50% death. In
contrast, if the cells were stimulated in the presence of
TGF-b1, the percentage of apoptotic cells was dramatically
decreased.
To study the mechanism by which TGF-b1 inhibits
AICD, we used the T cell hybridomas A1.1 and 2B4.11,
two cell lines used extensively to examine AICD (17, 30).
We first investigated the effect of TGF-b1 on AICD in
these T cell hybridomas. As expected, TGF-b1 decreased
anti-CD3–induced apoptosis in both cell types, as mea-
sured by propidium iodide uptake (Fig. 1 B) or DNA lad-
dering (Fig. 1 C).
TGF-b1 Inhibits Activation-induced FasL Expression. We
demonstrated previously that AICD in both A1.1 and
2B4.11 T cell hybridomas proceeds via expression of FasL
and subsequent Fas/FasL interaction (17). Therefore, we
envisioned three nonexclusive possibilities for the mecha-
nism of inhibition by TGF-b1: inhibition of FasL expres-
sion, inhibition of Fas expression, and/or inhibition of the
Fas signaling pathway. To assess whether the inhibitory ac-
tivity of TGF-b1 alters Fas or FasL gene expression, RNA
was isolated and analyzed by semiquantitative RT-PCR.
A1.1 T cell hybridomas constitutively expressed a low level
of Fas mRNA, which increased approximately two- to
threefold after activation, and TGF-b1 only slightly de-
creased Fas expression at high doses (10–100 ng/ml; Fig. 2
A). In contrast, activation-induced expression of FasL in
A1.1 cells was greatly reduced by TGF-b1 at 0.1 ng/ml
and completely prevented at higher concentrations (Fig. 2
A). This decrease in FasL mRNA was reflected in the bio-
logical activity of this molecule, since A1.1 cells that were
stimulated with anti-CD3 antibody in the presence of
TGF-b1 did not induce apoptosis in Fas1 target cells (Fig.
2 B). Addition of TGF-b1 to the cocultures of L1210-Fas
target cells and activated A1.1 cells (6 h after activation),
rather than to the A1.1 cells at the onset of the activation,
failed to inhibit cytotoxicity (Fig. 2 B). These data suggest234 TGF-b1 Regulates FasL Expression via c-Myc
that TGF-b1 inhibits AICD by preventing FasL expression
and not via a blockade in the Fas signaling pathway. To
confirm the absence of effect of TGF-b1 on Fas signaling,
we treated A1.1 cells with recombinant soluble FasL cross-
linked with anti-Flag antibody (31) in the absence or pres-
ence of TGF-b1. As shown in Fig. 3, addition of TGF-b1
did not prevent soluble FasL–induced apoptosis in A1.1
cells.
TGF-b1 Inhibits c-myc Expression in T Cell Hybridomas.
TGF-b1 has been reported to downregulate constitutive
and inducible c-Myc expression in two constitutively acti-
vated murine T clones (29). To determine whether TGF-b1
regulates c-myc expression in T cell hybridomas, we ana-
lyzed the mRNA expression of the c-myc gene by RT-
PCR. TGF-b1 induced a dose-dependent inhibition of
constitutive c-myc expression (Fig. 4 A), whereas CsA,
which also completely blocked FasL mRNA expression
(Fig. 2 A), did not inhibit c-myc expression. This effect was
confirmed by analysis of c-Myc protein expression after
treatment of A1.1 cells for 8 h in the presence of 1 ng/ml
TGF-b1 (Fig. 4 B, lanes 1 and 2).
Regulation of FasL Expression and AICD by TGF-b1 Is
Mediated by c-Myc. We next addressed whether the inhi-
bition of FasL expression by TGF-b1 was a consequence of
c-myc downregulation. To test the role of c-Myc on FasL
inhibition induced by TGF-b1, we prepared stable trans-
fectants constitutively expressing a chimeric molecule com-
posed of c-Myc and the estrogen-binding domain of the
Figure 2. TGF-b1 inhibits activation-induced apoptosis by blocking
FasL mRNA expression and functional activity. (A) TGF-b1 inhibits ac-
tivation-induced FasL mRNA expression. RT-PCR analysis of total
mRNA obtained from A1.1 cells incubated in medium alone or activated
for 4 h by anti-CD3 antibodies in the presence or absence of increasing
concentrations of TGF-b1 or CsA (100 ng/ml). mRNA was reverse tran-
scribed by using oligo(dT) primers, and PCR amplification was per-
formed using different numbers of cycles with the primers pairs indicated.
The products were electrophoresed on 1.5% agarose gel and stained with
ethidium bromide. (B) TGF-b1 inhibits AICD by modulating the ex-
pression of FasL functional activity but not by blocking the signaling
through Fas receptor. A1.1 cells were activated at time 0 with coated
anti-CD3 antibodies in the presence or absence of different concentra-
tions of TGF-b1. The L1210 or L1210-Fas target cells were not added at
this time. The T cell hybridomas were then cultured for 6 h to allow FasL
expression, harvested, washed twice, and incubated for an additional 8 h
with [3H]TdR-labeled L1210 or L1210-Fas target cells. In a parallel ex-
periment, A1.1 cells were activated with anti-CD3 alone and TGF-b1
was added when A1.1 and target cells were mixed (T 5 16 h). Percent-
age of DNA fragmentation was calculated as described in Materials and
Methods.
Figure 3. TGF-b1 does not
block recombinant soluble FasL–
induced apoptosis. A1.1 T cell hy-
bridomas were preincubated for
1 h in the presence of TGF-b1
(10 ng/ml) and then treated with
different doses of soluble recombi-
nant human FasL (sFasL). 15 min
after addition of soluble FasL,
anti-Flag M2 antibody (1 mg/ml)
was added to cross-link soluble
FasL. After 12 h incubation, per-
centage of apoptosis was assessed
by propidium iodide uptake and
analyzed using a FACScan®.
Figure 4. TGF-b1 inhibits endogenous c-myc mRNA and protein ex-
pression but not ectopic expression of the chimeric Myc-ER protein. (A)
TGF-b1 inhibits c-myc mRNA expression. RT-PCR analysis of total
mRNA obtained from A1.1 cells incubated in medium alone or activated
for 4 h by anti-CD3 antibody with the indicated concentration of TGF-
b1 or CsA (100 ng/ml). mRNA was reverse transcribed by using
oligo(dT) primers, and PCR amplification was performed using different
numbers of cycles with the primers pairs indicated. The products were re-
solved by agarose gel electrophoresis. (B) TGF-b1 inhibits constitutive
endogenous c-Myc protein expression but not ectopic expression of the
chimeric Myc-ER protein. Total cell extracts were prepared from A1.1
or A1.1 Myc-ER cells treated for 8 h in the presence or absence of
TGF-b1 (1 ng/ml). Samples were analyzed by immunoblot analysis using
anti–human c-Myc antibody.235 Genestier et al.
estrogen receptor (38; Myc-ER). In these A1.1 Myc-ER
cells, the activity of the chimeric Myc protein is dependent
on the availability of exogenous 4-OHT (35). The expres-
sion of Myc-ER and endogenous c-Myc protein before
and after treatment of A1.1 Myc-ER cells with TGF-b1
was then assessed by immunoblotting with anti–c-Myc
antibody. As shown in Fig. 4 B (lanes 3 and 4), A1.1
Myc-ER cells expressed both Myc-ER and endogenous
c-Myc protein, and after TGF-b1 treatment the endog-
enous c-Myc protein completely disappeared while the
chimeric Myc-ER protein remained.
A1.1 or A1.1 Myc-ER cells were then preincubated in
the presence or absence of 4-OHT (50 nM) for 4 h to in-
duce Myc-ER function (35), and activation-induced FasL
mRNA expression was analyzed by RT-PCR. Results are
shown in Fig. 5 A. In all cases, treatment with anti-CD3
induced the expression of FasL (lanes 2) versus unstimu-
lated cells (lanes 1). In the absence of Myc-ER function
(A1.1 cells with or without 4-OHT, or A1.1 Myc-ER
without 4-OHT), TGF-b1 treatment inhibited expression
of FasL in the anti-CD3–stimulated cells (lanes 3). Strik-
ingly, however, functional Myc-ER (A1.1 Myc-ER cells
with 4-OHT) permitted expression of FasL in anti-CD3–
stimulated cells even in the presence of TGF-b1. Thus, the
ability of TGF-b1 to inhibit c-Myc expression is directly
responsible for its ability to block FasL expression in these
cells. In contrast, CsA, which inhibits FasL expression by
inhibition of nuclear factor of activated T cells (NF-AT)
activity (39, 40), was effective in inhibiting A1.1 Myc-ER
cells even in the presence of 4-OHT (Fig. 5 A).
The ability of c-Myc function to reverse the inhibitory
activity of TGF-b1 on FasL expression also affected the
regulation of AICD in A1.1 Myc-ER cells. In the absence
of 4-OHT, TGF-b1 inhibited AICD in A1.1 Myc-ER
cells. However, after addition of 50 nM 4-OHT, TGF-b1
was ineffective in inhibiting AICD in A1.1 Myc-ER cells
(Fig. 5 B). No effect was seen of 4-OHT in the parental
A1.1 cells. Thus, active Myc-ER reversed the inhibition of
AICD by TGF-b1, most likely via activation-induced FasL
expression. To further confirm these data, we cloned A1.1
Myc-ER cells and selected three clones which express the
Myc-ER fusion protein (Fig. 6 A). TGF-b1 prevented
AICD in the absence of 4-OHT. As with the “bulk” trans-
fectants, addition of 4-OHT almost completely reversed
the protective effect of TGF-b1 on AICD for all three
Myc-ER clones but not for A1.1 parental cells (Fig. 6 B).
Thus, when c-Myc activity is maintained, no inhibitory
effect of TGF-b1 on either FasL expression or AICD in T
cell hybridomas is observed. These results formally demon-
strate that the ability of TGF-b1 to inhibit FasL expression
and subsequent AICD is dependent on its ability to down-
regulate c-Myc.
TGF-b1–mediated Inhibition of c-Myc Does Not Block Activa-
tion-induced FasL Expression via Perturbation of the Cell Cycle.
In some models, TGF-b1 has been shown to cause cell cy-
cle arrest in G1 by upregulation of CDK inhibitors (25) or
by repression of Cdc25A, a CDK tyrosine phosphatase
which activates CDK (26). Since Cdc25A is transcription-
ally induced by c-Myc (41), we addressed whether TGF-
b1–induced inhibition of c-Myc decreased FasL expression
via cell cycle arrest. As shown in Fig. 7, addition of TGF-
b1, ASc-myc, or NSc-myc oligonucleotides to A1.1 cells cul-
tured in medium alone did not modify the proportion of
cells in G0/G1, S, or G2/M phase of the cell cycle. When
A1.1 cells were activated with anti-CD3 alone, live cells
accumulated in G0/G1 phase with a decreased proportion
of cells in S and G2/M phase at 24 h as described (30). Ad-
dition of TGF-b1, ASc-myc, or NSc-myc oligonucleotides
did not significantly alter this profile (Fig. 7). Although
TGF-b1 and ASc-myc oligonucleotides did not modify the
proportion of cycling cells, they decreased AICD in A1.1
cells from 60 to 20% and 60 to 29%, respectively, after 12 h
of culture (21; data not shown). DNA synthesis studies us-
ing [3H]TdR incorporation also demonstrated that TGF-
b1 did not inhibit proliferation of unactivated A1.1 cells
(26,678 6 2,343 cpm in control cells vs. 24,310 6 4,121
Figure 5. Ectopic expression of chimeric Myc-ER protein prevents
TGF-b1–mediated inhibition of FasL mRNA and subsequent AICD. (A)
Functional Myc-ER interferes with the inhibitory effect of TGF-b1 on
activation-induced FasL expression in A1.1 cells. A1.1 or A1.1 Myc-ER
cells exposed to 4-OHT (50 nM) were first preincubated for 4 h with the
drug, which was then also present during subsequent culture. Cells were
then incubated in medium alone (lane 1) or activated for 4 h with anti-
CD3 antibodies (lanes 2, 3, and 4). 1 ng/ml TGF-b1 (lane 3) or 100 ng/
ml CsA (lane 4) was added to some cultures. FasL expression was then as-
sessed by RT-PCR. (B) Ectopic expression of a chimeric Myc-ER pro-
tein prevents AICD after TGF-b1 treatment. A1.1 or A1.1 Myc-ER T
hybridoma cells were first preincubated for 4 h in the presence or absence
of 4-OHT (50 nM) and then activated for 16 h with anti-CD3 antibodies
with the indicated concentrations of TGF-b1 (1 ng/ml) or CsA (100 ng/ml).
Cell death was assessed by propidium iodide uptake using a FACScan®.236 TGF-b1 Regulates FasL Expression via c-Myc
cpm in TGF-b1–treated cells), whereas [3H]TdR incorpo-
ration of activated A1.1 cells was almost completely inhib-
ited with or without addition of TGF-b1 (1,625 6 243
cpm in anti-CD3–treated cells vs. 2,111 6 328 cpm in
anti-CD3 plus TGF-b1–treated cells).
Discussion
AICD in vivo has been proposed first to limit the expan-
sion of an immune response by eliminating effector cells
that are no longer needed, and second to eliminate poten-
tially autoreactive T cells that have escaped thymic selec-
tion (15). Evidence from lpr or gld mice, deficient in func-
tional Fas and FasL, respectively, suggested that Fas/FasL
interactions are crucial for the regulation of these physio-
logical processes. Experiments using antagonists of Fas/FasL
interaction such as Fas–Fc fusion protein or a neutralizing
anti-Fas mAb further demonstrated the direct involvement
of these molecules in AICD of mature T cells (16–20). In
this study, we have shown that TGF-b1, which is known
to block the process of AICD in T cells (13, 14), does so by
the selective inhibition of activation-induced FasL expres-
sion. This was demonstrated by analysis of FasL mRNA
expression by RT-PCR and by functional assays. Indeed,
many tumors, such as malignant astrocytoma, produce a
high level of TGF-b1 (42) which might inhibit FasL ex-
pression on CD81 T cells and therefore counteract their
cytotoxic function.
Interestingly, there is also an inhibitory effect of TGF-b1
on perforin and granzyme B mRNA expression as well as
serine esterase activity in CD81 T cells, and this serves to
block cytotoxic function of perforin-dependent killers (43,
44). Whether this represents a similar requirement for
c-Myc in the expression of these important components of
cytotoxic granules is not known.
In contrast to its effects on FasL expression, we observed
that TGF-b1 does not significantly affect activation-induced
Figure 6. Ectopic expression of chimeric Myc-ER protein prevents
TGF-b1–mediated inhibition of AICD in A1.1 T cell hybridomas. (A)
Expression of Myc-ER fusion protein in A1.1 Myc-ER clones. Total cell
extracts were prepared from three different A1.1 Myc-ER clones. Sam-
ples were analyzed by immunoblot analysis using anti–human c-Myc an-
tibody. (B) Ectopic expression of a chimeric Myc-ER protein prevents
AICD after TGF-b1 treatment. A1.1 or A1.1 Myc-ER clones were acti-
vated for 16 h with anti-CD3 antibodies with the indicated concentra-
tions of TGF-b1 (1 ng/ml) in the presence or absence of 4-OHT (50 nM)
added at time 0 of the activation. Cell death was assessed by propidium
iodide uptake using a FACScan®.
Figure 7. TGF-b1 as well as ASc-myc oligonucleotides do not induce
perturbation of the cell cycle in A1.1 T cell hybridomas. 106 A1.1 cells
were untreated or activated with anti-CD3 in the presence of 5 mM ASc-
myc or NSc-myc oligonucleotides added 4 h before activation or with
TGF-b1 (10 ng/ml) added 1 h before activation. Cells were harvested at
the indicated times, and cell cycle analysis was performed by propidium
iodide staining after permeabilization with Triton X-100. The percentage
of cells in G0/G1 (A), S (B), and G2/M (C) phase of the cell cycle was
determined for each condition (data shown are means 6 SD, n 5 3).237 Genestier et al.
Fas expression in T cell hybridomas. T cell activation
induces the appearance of Fas on naive T cells and an
increased expression on some T cell hybridomas (15, 17).
In the latter, CsA does not inhibit the activation-induced
increase in Fas mRNA expression, although it does par-
tially inhibit cell surface Fas (39). Similar observations have
been made for retinoic acid analogues, which inhibit FasL
but not Fas expression (20, 45). Thus, Fas is regulated in T
cells in a fundamentally different way from its ligand, and
this includes the effect of TGF-b1. However, in contrast to
T cells, progenitors of dendritic cells show reduced Fas ex-
pression when cultured with TGF-b1 (6). Whether or not
this is related to a requirement for c-Myc or some other
TGF-b1–regulated factors is not known.
In our studies, the inhibition of FasL by TGF-b1 in T
cell hybridomas correlated with a decrease in c-myc mRNA
levels. This is in agreement with previous studies showing
that TGF-b1 is a potent inhibitor of c-Myc expression in
various cell types and in particular in mature T cells (27–29,
46). Our experiments using ectopic expression of the chi-
meric Myc-ER protein have now formally shown that the
inhibition of FasL induced by TGF-b1 is a direct conse-
quence of its downregulation of c-Myc expression.
The c-myc oncogene has been implicated in the control
of cell proliferation and differentiation, as well as neoplastic
transformation (47). Overexpression or inappropriate ex-
pression of the c-myc gene has been found to promote apop-
tosis in fibroblasts (48, 49). Recently, Hueber et al. (23)
reported that c-myc–induced apoptosis of serum-starved
fibroblasts requires the expression and function of Fas and
FasL. Although they showed that this was associated with
an increased susceptibility to Fas-induced apoptosis, they
did not rule out a role for c-Myc in driving expression of
FasL. We demonstrated previously that c-Myc function is
required for AICD in T cells, using c-myc antisense oligo-
nucleotides (21) and dominant negative mutants of Myc or
Max, which antagonize the functional Myc/Max het-
erodimer (22). Our finding that TGF-b1 inhibits FasL ex-
pression via downregulation of c-myc mRNA expression
strongly suggests that the requirement for c-Myc during
AICD may be at the level of FasL expression.
There is evidence that proliferating T lymphocytes are
more susceptible to AICD during the S phase of their cell
cycle (50). Although TGF-b1 causes cell cycle arrest in G1
in some models (24–26) and can also block constitutive
c-Myc expression in T cell hybridomas, surprisingly we did
not find a significant difference in cell cycle distribution
when we compared cells stimulated for 3–24 h in the pres-
ence or absence of TGF-b1. This observation could be ex-
plained by the fact that residual c-Myc expression may be
sufficient for cell cycle progression but not for FasL expres-
sion. Nevertheless, our finding argues against the possibility
that TGF-b1 regulates FasL expression and subsequent
AICD via perturbation of the cell cycle. This result is con-
sistent with the finding that TGF-b1 promotes effector T
cell expansion in association with IL-2 in murine Th2
clones (14).
In contrast to T cells, TGF-b1 promotes apoptosis in
immature B cell lines such as WEHI 231 or CH31 cells
(51–54). Apoptosis induced by TGF-b1 in these cells is
preceded by a decline in c-Myc expression, and stabiliza-
tion or ectopic expression of c-Myc prevented this cell
death (52, 55). More recently, Arsura et al. (51) demon-
strated that inhibition of c-Myc expression and subsequent
apoptosis in B cells after TGF-b1 treatment were a conse-
quence of the transcriptional activation of IkBa, which
prevented the direct regulation of c-Myc expression by
NF-kB. Whether this plays a role in TGF-b1–induced
downregulation of c-Myc in T cells is unknown.
The relevance of the antiapoptotic effect of TGF-b1
might be associated with the observation that addition of
this cytokine together with IL-2 not only blocked AICD
but also enhanced effector T cell expansion and long-term
T cell survival (13, 14). These results strongly suggest that
TGF-b1 may be one of the cytokines involved in T cell
memory generation. The persistence of memory T cells has
been suggested to be dependent on periodic restimulation
by specific or cross-reacting antigens (56, 57). TGF-b1
might be necessary for inhibiting FasL expression, thus per-
mitting the generation and survival of memory T cells (15).
The roles played in the development and function of the
immune system by c-Myc and FasL, under the control of
TGF-b1, are likely to be diverse. TGF-b1–deficient mice
have smaller spleens with less distinct white pulp and fewer
Peyer’s patches with less distinct germinal centers than
those of normal littermates (58), and it is thus possible that
this is a consequence of deregulated FasL expression, nor-
mally controlled by this cytokine.
The authors thank G. Wong for providing reagents, P. Golstein for L1210 and L1210-Fas cell lines, G.I.
Evan for the pBABE puroMyc-ER G525R, and W. Force for assistance with retrovirus production. We
also thank T. Lin and H. Beere for critical reading of the manuscript. 
This work was supported in part by the Association pour la Recherche sur le Cancer (ARC) and the Hu-
man Frontier Science Program (to L. Genestier), and by National Institutes of Health grant GM52735 (to
D.R. Green). This is publication #227 from the La Jolla Institute for Allergy and Immunology.
Address correspondence to Douglas R. Green, Division of Cellular Immunology, La Jolla Institute for Al-
lergy and Immunology, 10355 Science Center Rd., San Diego, CA 92121. Phone: 619-558-3500; Fax:
619-558-3526; E-mail: dgreen5240@aol.com238 TGF-b1 Regulates FasL Expression via c-Myc
T. Brunner’s present address is Division of Immunopathology, Institute for Pathology, University of Bern,
3010 Bern, Switzerland.
Received for publication 24 April 1998 and in revised form 13 August 1998.
References
1. Massague, J. 1990. The transforming growth factor-beta fam-
ily. Annu. Rev. Cell Biol. 6:597–641.
2. Kasid, A., G.I. Bell, and E.P. Director. 1988. Effects of trans-
forming growth factor-beta on human lymphokine-activated
killer cell precursors. Autocrine inhibition of cellular prolifer-
ation and differentiation to immune killer cells. J. Immunol.
141:690–698.
3. Fontana, A., K. Frei, S. Bodmer, E. Hofer, M.H. Schreier,
M.A. Palladino, Jr., and R.M. Zinkernagel. 1989. Trans-
forming growth factor-beta inhibits the generation of cyto-
toxic T cells in virus-infected mice. J. Immunol. 143:3230–
3244.
4. Bright, J.J., L.D. Kerr, and S. Sriram. 1997. TGF-beta inhib-
its IL-2-induced tyrosine phosphorylation and activation of
Jak-1 and Stat 5 in T lymphocytes. J. Immunol. 159:175–183.
5. Moses, H.L., E.Y. Yang, and J.A. Pietenpol. 1990. TGF-beta
stimulation and inhibition of cell proliferation: new mecha-
nistic insights. Cell. 63:245–247.
6. Riedl, E., H. Strobl, O. Majdic, and W. Knapp. 1997. TGF-
beta 1 promotes in vitro generation of dendritic cells by pro-
tecting progenitor cells from apoptosis. J. Immunol. 158:
1591–1597.
7. Swain, S.L., G. Huston, S. Tonkonogy, and A. Weinberg.
1991. Transforming growth factor-beta and IL-4 cause
helper T cell precursors to develop into distinct effector
helper cells that differ in lymphokine secretion pattern and
cell surface phenotype. J. Immunol. 147:2991–3000.
8. Johns, L.D., K.C. Flanders, G.E. Ranges, and S. Sriram.
1991. Successful treatment of experimental allergic encepha-
lomyelitis with transforming growth factor-beta 1. J. Immu-
nol. 147:1792–1796.
9. Kuruvilla, A.P., R. Shah, G.M. Hochwald, H.D. Liggitt,
M.A. Palladino, and G.J. Thorbecke. 1991. Protective effect
of transforming growth factor beta 1 on experimental au-
toimmune diseases in mice. Proc. Natl. Acad. Sci. USA. 88:
2918–2921.
10. Santambrogio, L., G.M. Hochwald, B. Saxena, C.H. Leu,
J.E. Martz, J.A. Carlino, N.H. Ruddle, M.A. Palladino, L.I.
Gold, and G.J. Thorbecke. 1993. Studies on the mechanisms
by which transforming growth factor-beta (TGF-beta) pro-
tects against allergic encephalomyelitis. Antagonism between
TGF-beta and tumor necrosis factor. J. Immunol. 151:1116–
1127.
11. Lee, H.M., and S. Rich. 1991. Co-stimulation of T cell pro-
liferation by transforming growth factor-beta 1. J. Immunol.
147:1127–1133.
12. Rich, S., N. Van Nood, and H.M. Lee. 1996. Role of alpha
5 beta 1 integrin in TGF-beta 1-costimulated CD81 T cell
growth and apoptosis. J. Immunol. 157:2916–2923.
13. Cerwenka, A., H. Kovar, O. Majdic, and W. Holter. 1996.
Fas- and activation-induced apoptosis are reduced in human
T cells preactivated in the presence of TGF-beta 1. J. Immu-
nol. 156:459–464.
14. Zhang, X., L. Giangreco, H.E. Broome, C.M. Dargan, and
S.L. Swain. 1995. Control of CD4 effector fate: transforming
growth factor beta 1 and interleukin 2 synergize to prevent
apoptosis and promote effector expansion. J. Exp. Med. 182:
699–709.
15. Lynch, D.H., F. Ramsdell, and M.R. Alderson. 1995. Fas
and FasL in the homeostatic regulation of immune responses.
Immunol. Today. 16:569–574.
16. Alderson, M.R., T.W. Tough, T. Davis-Smith, S. Braddy,
B. Falk, K.A. Schooley, R.G. Goodwin, C.A. Smith, F.
Ramsdell, and D.H. Lynch. 1995. Fas ligand mediates activa-
tion-induced cell death in human T lymphocytes. J. Exp.
Med. 181:71–77.
17. Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi,
F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F.
Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand
interaction mediates activation-induced apoptosis in T-cell
hybridomas. Nature. 373:441–444.
18. Dhein, J., H. Walczak, C. Baumler, K.M. Debatin, and P.H.
Krammer. 1995. Autocrine T-cell suicide mediated by APO-
1/(Fas/CD95). Nature. 373:438–441.
19. Ju, S.T., D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib,
D.H. Sherr, B.Z. Stanger, and A. Marshak-Rothstein. 1995.
Fas(CD95)/FasL interactions required for programmed cell
death after T-cell activation. Nature. 373:444–448.
20. Yang, Y., M. Mercep, C.F. Ware, and J.D. Ashwell. 1995.
Fas and activation-induced Fas ligand mediate apoptosis of T
cell hybridomas: inhibition of Fas ligand expression by retin-
oic acid and glucocorticoids. J. Exp. Med. 181:1673–1682.
21. Shi, Y., J.M. Glynn, L.J. Guilbert, T.G. Cotter, R.P. Bisson-
nette, and D.R. Green. 1992. Role for c-myc in activation-
induced apoptotic cell death in T cell hybridomas. Science.
257:212–214.
22. Bissonnette, R.P., A. McGahon, A. Mahboubi, and D.R.
Green. 1994. Functional Myc-Max heterodimer is required
for activation-induced apoptosis in T cell hybridomas. J. Exp.
Med. 180:2413–2418.
23. Hueber, A.O., M. Zornig, D. Lyon, T. Suda, S. Nagata, and
G.I. Evan. 1997. Requirement for the CD95 receptor-ligand
pathway in c-Myc-induced apoptosis. Science. 278:1305–
1309.
24. Ewen, M.E., H.K. Sluss, L.L. Whitehouse, and D.M. Living-
ston. 1993. TGF beta inhibition of Cdk4 synthesis is linked
to cell cycle arrest. Cell. 74:1009–1020.
25. Hannon, G.J., and D. Beach. 1994. p15INK4B is a potential
effector of TGF-beta-induced cell cycle arrest. Nature. 371:
257–261.
26. Iavarone, A., and J. Massague. 1997. Repression of the CDK
activator Cdc25A and cell-cycle arrest by cytokine TGF-beta
in cells lacking the CDK inhibitor p15. Nature. 387:417–422.
27. Coffey, R.J., Jr., C.C. Bascom, N.J. Sipes, R. Graves-Deal,
B.E. Weissman, and H.L. Moses. 1988. Selective inhibition
of growth-related gene expression in murine keratinocytes by
transforming growth factor beta. Mol. Cell. Biol. 8:3088–
3093.
28. Pietenpol, J.A., R.W. Stein, E. Moran, P. Yaciuk, R. Schle-
gel, R.M. Lyons, M.R. Pittelkow, K. Munger, P.M. How-
ley, and H.L. Moses. 1990. TGF-beta 1 inhibition of c-myc
transcription and growth in keratinocytes is abrogated by vi-239 Genestier et al.
ral transforming proteins with pRB binding domains. Cell.
61:777–785.
29. Ruegemer, J.J., S.N. Ho, J.A. Augustine, J.W. Schlager,
M.P. Bell, D.J. McKean, and R.T. Abraham. 1990. Regula-
tory effects of transforming growth factor-beta on IL-2- and
IL-4-dependent T cell-cycle progression. J. Immunol. 144:
1767–1776.
30. Ashwell, J.D., R.E. Cunningham, P.D. Noguchi, and D.
Hernandez. 1987. Cell growth cycle block of T cell hybrido-
mas upon activation with antigen. J. Exp. Med. 165:173–194.
31. Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei,
A. Fontana, and J. Tschopp. 1998. Conversion of mem-
brane-bound Fas(CD95) ligand to its soluble form is associ-
ated with downregulation of its proapoptotic activity and loss
of liver toxicity. J. Exp. Med. 187:1205–1213.
32. Benhamou, L.E., T. Watanabe, D. Kitamura, P.A. Cazenave,
and P. Sarthou. 1994. Signaling properties of anti-immuno-
globulin–resistant variants of WEHI-231 B lymphoma cells.
Eur. J. Immunol. 24:1993–1999.
33. Pear, W.S., G.P. Nolan, M.L. Scott, and D. Baltimore. 1993.
Production of high-titer helper-free retroviruses by transient
transfection. Proc. Natl. Acad. Sci. USA. 90:8392–8396.
34. Force, W.R., T.C. Cheung, and C.F. Ware. 1997. Domi-
nant negative mutants of TRAF3 reveal an important role for
the coiled coil domains in cell death signaling by the lym-
photoxin-beta receptor. J. Biol. Chem. 272:30835–30840.
35. Littlewood, T.D., D.C. Hancock, P.S. Danielian, M.G.
Parker, and G.I. Evan. 1995. A modified oestrogen receptor
ligand-binding domain as an improved switch for the regula-
tion of heterologous proteins. Nucleic Acids Res. 23:1686–
1690.
36. Nicoletti, I., G. Migliorati, M.C. Pagliacci, F. Grignani, and
C. Riccardi. 1991. A rapid and simple method for measuring
thymocyte apoptosis by propidium iodide staining and flow
cytometry. J. Immunol. Methods. 139:271–279.
37. Shi, Y.F., B.M. Sahai, and D.R. Green. 1989. Cyclosporin A
inhibits activation-induced cell death in T-cell hybridomas
and thymocytes. Nature. 339:625–626.
38. Eilers, M., D. Picard, K.R. Yamamoto, and J.M. Bishop.
1989. Chimaeras of myc oncoprotein and steroid receptors
cause hormone-dependent transformation of cells. Nature.
340:66–68.
39. Brunner, T., N.J. Yoo, D. LaFace, C.F. Ware, and D.R.
Green. 1996. Activation-induced cell death in murine T cell
hybridomas. Differential regulation of Fas (CD95) versus Fas
ligand expression by cyclosporin A and FK506. Int. Immunol.
8:1017–1026.
40. Latinis, K.M., L.A. Norian, S.L. Eliason, and G.A. Koretzky.
1997. Two NFAT transcription factor binding sites partici-
pate in the regulation of CD95 (Fas) ligand expression in ac-
tivated human T cells. J. Biol. Chem. 272:31427–31434.
41. Galaktionov, K., X. Chen, and D. Beach. 1996. Cdc25 cell-
cycle phosphatase as a target of c-myc. Nature. 382:511–517.
42. Bodmer, S., K. Strommer, K. Frei, C. Siepl, N. de Tribolet,
I. Heid, and A. Fontana. 1989. Immunosuppression and
transforming growth factor-beta in glioblastoma. Preferential
production of transforming growth factor-beta 2. J. Immunol.
143:3222–3229.
43. Inge, T.H., K.M. McCoy, B.M. Susskind, S.K. Barrett, G.
Zhao, and H.D. Bear. 1992. Immunomodulatory effects of
transforming growth factor-beta on T lymphocytes. Induc-
tion of CD8 expression in the CTLL-2 cell line and in nor-
mal thymocytes. J. Immunol. 148:3847–3856.
44. Smyth, M.J., S.L. Strobl, H.A. Young, J.R. Ortaldo, and
A.C. Ochoa. 1991. Regulation of lymphokine-activated
killer activity and pore-forming protein gene expression in
human peripheral blood CD81 T lymphocytes. Inhibition
by transforming growth factor-beta. J. Immunol. 146:3289–
3297.
45. Bissonnette, R.P., T. Brunner, S.B. Lazarchik, N.J. Yoo,
M.F. Boehm, D.R. Green, and R.A. Heyman. 1995. 9-cis
retinoic acid inhibition of activation-induced apoptosis is
mediated via regulation of fas ligand and requires retinoic
acid receptor and retinoid X receptor activation. Mol. Cell.
Biol. 15:5576–5585.
46. Green, D.R., A. Mahboubi, W. Nishioka, S. Oja, F. Eche-
verri, Y. Shi, J. Glynn, Y. Yang, J. Ashwell, and R. Bisson-
nette. 1994. Promotion and inhibition of activation-induced
apoptosis in T-cell hybridomas by oncogenes and related sig-
nals. Immunol. Rev. 142:321–342.
47. Luscher, B., and R.N. Eisenman. 1990. New light on Myc
and Myb. Part I. Myc. Genes Dev. 4:2025–2035.
48. Evan, G.I., A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H.
Land, M. Brooks, C.M. Waters, L.Z. Penn, and D.C. Han-
cock. 1992. Induction of apoptosis in fibroblasts by c-myc
protein. Cell. 69:119–128.
49. Klefstrom, J., E. Arighi, T. Littlewood, M. Jäättel, E. Saksela,
G.I. Evan, and K. Alitalo. 1997. Induction of TNF-sensitive
cellular phenotype by c-Myc involves p53 and impaired NF-
kappaB activation. EMBO (Eur. Mol. Biol. Organ.) J. 16:
7382–7392.
50. Boehme, S.A., and M.J. Lenardo. 1993. Propriocidal apopto-
sis of mature T lymphocytes occurs at S phase of the cell cy-
cle. Eur. J. Immunol. 23:1552–1560.
51. Arsura, M., M. Wu, and G.E. Sonenshein. 1996. TGF beta 1
inhibits NF-kappa B/Rel activity inducing apoptosis of B
cells: transcriptional activation of I kappa B alpha. Immunity.
5:31–40.
52. Fischer, G., S.C. Kent, L. Joseph, D.R. Green, and D.W.
Scott. 1994. Lymphoma models for B cell activation and tol-
erance. X. Anti-mu–mediated growth arrest and apoptosis of
murine B cell lymphomas is prevented by the stabilization of
myc. J. Exp. Med. 179:221–228.
53. Sonenshein, G.E. 1997. Down-modulation of c-myc expres-
sion induces apoptosis of B lymphocyte models of tolerance
via clonal deletion. J. Immunol. 158:1994–1997.
54. Warner, G.L., J.W. Ludlow, D.A. Nelson, A. Gaur, and
D.W. Scott. 1992. Anti-immunoglobulin treatment of mu-
rine B-cell lymphomas induces active transforming growth
factor beta but pRB hypophosphorylation is transforming
growth factor beta independent. Cell Growth Differ. 3:175–181.
55. Wu, M., M. Arsura, R.E. Bellas, M.J. FitzGerald, H. Lee,
S.L. Schauer, D.H. Sherr, and G.E. Sonenshein. 1996. Inhi-
bition of c-myc expression induces apoptosis of WEHI 231
murine B cells. Mol. Cell. Biol. 16:5015–5025.
56. Beverley, P.C. 1990. Is T-cell memory maintained by cross-
reactive stimulation? Immunol. Today. 11:203–205.
57. Gray, D., and P. Matzinger. 1991. T cell memory is short-
lived in the absence of antigen. J. Exp. Med. 174:969–974.
58. Shull, M.M., I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Die-
bold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin,
et al. 1992. Targeted disruption of the mouse transforming
growth factor-beta 1 gene results in multifocal inflammatory
disease. Nature. 359:693–699.